Importantly, ganetespib also induced degradation of IGF-IR and phosphorylated EGFR receptors, previously implicated in the pathogenesis of prostate cancer, as well as the downstream effectors AKT and p70 S6K, in LNCaP cells (Fig. 1A). Here, IGF1R is linked to prostate cancer.